# Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors.Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026.

*biotech · news · 2026-05-04 · The Manila Times*

## Key points

- Windward Bio raised $165M in crossover financing, including new investors RA Capital and Sanofi Ventures.
- WIN378's Phase 2/3 asthma study POLARIS is fully recruited, with initial data expected in late 2026.
- WIN378 enables twice-yearly dosing and could become the first ultra long-acting anti-TSLP for asthma and COPD.
- WIN027 is a bispecific antibody targeting TSLP and IL-13; proof-of-concept studies begin in Q4 2026.

**Companies:** Windward Bio, Sanofi Ventures, Novo Holdings, RA Capital Management, Janus Henderson Investors, Harbour BioMed, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, Pivotal bioVenture Partners
**Countries:** Switzerland

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/04/tmt-newswire/globenewswire/windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential/2334862)

---

Canonical: https://newsio.io/n/e5182fc0-cc73-4b47-89b8-16d11d269c45/led-by-orbimed-with-participation-from-ra-capital-management-janus-henderson-inv
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works